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Open access under CC BYActivity of the pterin- and folate-salvaging enzymes pteridine reductase 1 (PTR1) and dihydrofolate
reductase–thymidylate synthetase (DHFR-TS) is commonly measured as a decrease in absorbance at
340 nm, corresponding to oxidation of nicotinamide adenine dinucleotide phosphate (NADPH). Although
this assay has been adequate to study the biology of these enzymes, it is not amenable to support any
degree of routine inhibitor assessment because its restricted linearity is incompatible with enhanced
throughput microtiter plate screening. In this article, we report the development and validation of a non-
enzymatically coupled screening assay in which the product of the enzymatic reaction reduces cyto-
chrome c, causing an increase in absorbance at 550 nm. We demonstrate this assay to be robust and
accurate, and we describe its utility in supporting a structure-based design, small-molecule inhibitor
campaign against Trypanosoma brucei PTR1 and DHFR-TS.
 2009 Elsevier Inc. Open access under CC BY license.Human African trypanosomiasis (HAT),1 also known as sleeping
sickness, is a protozoan parasitic disease that causes death and dis-
ability across large undeveloped regions of sub-Saharan Africa [1].
Infection is caused by two subspecies of Trypanosoma brucei: T. b.
gambiense (endemic in central and western areas) and T. b. rhodes-
iense (predominantly found in southern and eastern Africa). Both
infections are fatal if left untreated. The early (hemolymphatic) stage
of the disease is treated by suramin or pentamidine, and the late
(central nervous system) stage is treated by eﬂornithine (T. b. gamb-
iense) or the arsenical drug melarsoprol (both forms). All currently
available drugs must be given by injection and suffer from serious
deﬁciencies such as unacceptable toxicity, poor efﬁcacy, high cost,
and the need for prolonged hospitalization.
Development of drug therapies for HAT has been largely disre-
garded over the past 60 years. Investment in drug discovery for this
and other ‘‘orphan” diseases has declined sufﬁciently such that lessarson).
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 license.than 1% of all new drugs over the past 25 years have targeted trop-
ical parasitic diseases [2]. This is largely due to the poverty associ-
ated with these neglected diseases and the consequent low
proﬁtability of developing and manufacturing drugs.
Pterins and folates are known to be essential for growth in
Leishmania spp. and related trypanosomatids [3,4], and biosyn-
thetic enzymes for de novo synthesis are lacking from their respec-
tive genomes [5]. Consequently, trypanosomatids possess multiple
biopterin and folate transporters with salvage pathways to convert
them into the reduced cofactors 5,6,7,8-tetrahydrobiopterin (H4B)
and 5,6,7,8-tetrahydrofolate (H4F) by means of pteridine reductase
1 (PTR1, EC 1.5.1.33) and the bifunctional, nicotinamide adenine
dinucleotide phosphate (NADPH)-dependent enzyme dihydrofo-
late reductase–thymidylate synthase (DHFR-TS, ECs 1.5.1.4 and
2.1.1.45, respectively). Due to the auxotrophic nature of these par-
asites for folates and pterins, the enzymes associated with their
metabolism have been investigated extensively as potential drug
targets [3,4].
DHFR-TS, together with serine hydroxymethyltransferase
(SHMT) or the glycine cleavage system (the former enzyme is pres-
ent in Leishmania major but not in T. brucei [5,6]), is responsible for
de novo synthesis of thymidylate (dTMP) required for DNA replica-
tion. Gene knockout studies indicate that dhfr-ts null mutants of
L. major and T. brucei are able to grow normally in culture provided
that thymidine is present in the medium [7,8]. T. brucei DHFR-TS
null mutants are unable to establish an infection in mice due to
the extremely low concentrations of thymidine in plasma [8]. In
contrast, L. major DHFR-TS null mutants cause low-grade infections
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the infected macrophage.
Disappointingly, DHFR-TS inhibitors, such as those commonly
used in the development of anticancer, antimalarial, and antibacte-
rial drugs, have not shown equivalent efﬁcacy against T. brucei [8].
As demonstrated elegantly by Beverley and coworkers for L. major
[10,11], PTR1, a broad-speciﬁcity, short-chain dehydrogenase, can
reduce dihydrofolate (H2F) to H4F, thereby circumventing inhibi-
tion of DHFR-TS. Therefore, it is likely that cooperative inhibition
of both trypanosomal enzymes may be required to produce an
effective therapy.
It is also possible that PTR1 may be a therapeutic target in its
own right given that its primary function is to sequentially reduce
biopterin (B) to 7,8-dihydrobiopterin (H2B) and H4B. The biological
function of pterins in trypanosomatids is unknown, andmany func-
tions reported for mammalian cells have been discounted [3,12,13].
L. major ptr1 mutants are viable provided that the medium is sup-
plementedwith H2B and H4B [10,14]. However, similar gene knock-
out and knockdown studies on bloodstream T. brucei suggest that
PTR1 is essential (N. Sienkiewicz and A. H. Fairlamb, unpublished).
The Drug Discovery Unit at the University of Dundee has been
established to undertake a fully integrated approach to neglected
disease drug discovery. Combining a variety of approaches to hit
discovery, including high-throughput screening, ligand- and struc-
ture-based design with medicinal chemistry, and drug metabolism
and pharmacokinetics (DMPK) capabilities, our goal is to deliver
drug candidates for HAT for entry into formal preclinical develop-
ment. To support this endeavor, a portfolio of targets has been
compiled and assessed [15] at Dundee fromworldwide research ef-
forts, with T. brucei DHFR-TS (TbDHFR-TS) and T. brucei PTR1
(TbPTR1) ranking high on this prioritized list.
The assay principally used for measuring DHFR-TS and PTR1
activity follows a spectrophotometric decrease in absorbance at
340 nm, corresponding to oxidation of NADPH in the presence of
H2F and H2B (or biopterin), respectively. However, this cuvette-
based assay is unsuitable for supporting any level of throughput
with the necessary robustness required to support a progressive
medicinal chemistry effort. Similarly, detection of enzyme activity
by high-performance liquid chromatography (HPLC) also presents
insufﬁcient throughput.
The development of a screening assay to support in vitro target
activity assessment that provides relevant accurate data and per-
forms consistently throughout a program contributes signiﬁcantly
to the success of a lead development project. Therefore, a robust
‘‘ﬁt for purpose” assay is a necessity in discovering initial chemical
starting points and the subsequent development of meaningful
structure–activity relationships for compound series. To enable
routine screening for small-molecule inhibitors of TbDHFR-TS
and TbPTR1, we developed and validated a nonenzymatically cou-
pled absorbance assay. Here the enzymatic products H4B and H4F
are coupled to the reduction of oxidized cytochrome c (cyt c
Fe3+), the formation of which can be measured as an increase in
absorbance at 550 nm. The assay is executed in a 96-well microti-
ter plate, with performance statistics commensurate with the long-
term support of a medicinal chemistry program.Materials and methods
Cloning and protein production of TbPTR1 and TbDHFR-TS
All plasmids used were sequenced by the University of Dundee
DNA Sequencing Service (http://www.dnaseq.co.uk) and veriﬁed
against the published database sequences.
TbPTR1 was expressed and puriﬁed as the N-terminal hexahis-
tidine-tagged protein as described previously [16].The 1584-nucleotide sequence (accession no. TBU20781) encod-
ing the full-length TbDHFR-TS was obtained by polymerase chain
reaction (PCR) fromT. bruceistrain427genomicDNA(kindlyprovided
byM. Lucia L. Güther, University ofDundee) using the forwardprimer
50-CTGGATCCATGCTCAGTCTTACGCGTATCCTCCG-30 and the reverse
primer 50-GACTCGAGCTACACCGCCATCTCCATAGAAATTACG-30. The
underlined bases represent restriction sites for BamHI and XhoI,
respectively, andwere used for cloning into a pFastBac1 bacculovirus
expression vector (Invitrogen) that had been modiﬁed to encode a
glutathioneS-transferase (GST) tag followedbyaPreScissionprotease
recognition sequence, resulting in the ﬁnal bacculovirus expression
construct pFastBac GST–TbDHFR-TS. Recombinant protein was pro-
duced using the Bac-to-Bac system (Invitrogen) following themanu-
facturer’s protocol. Bacculovirus at amultiplicity of infection of 5was
used to infect Spodoptera frugiperda 21 cells (1.5  106/ml). The in-
fected cells were harvested 48 h postinfection, and the GST-tagged
protein was puriﬁed on glutathione (GSH)–Sepharose (GE Health-
care). TbDHFR-TS was unstable on cleavage of the GST tag; therefore,
all experiments were carried out using GST-tagged protein.
Determination of enzyme concentration
TbPTR1 enzyme concentration was determined spectrophoto-
metrically (extinction coefﬁcient at 260 nm = 14,815 M1 cm1).
Because tightly bound folate can interfere with absorbance at
260 and 280 nm, the concentration of TbDHFR-TS was determined
using Coomassie blue reagent [17].
The concentration of catalytically active enzyme in each prepa-
ration was determined using a titration of enzyme in the presence
of excess inhibitor, methotrexate (MTX), to calculate the concen-
tration of active sites in each sample. This concentration was used
for all subsequent work.
Novel screening assay protocol: Assay conditions
TbPTR1 activity was assayed in a buffer containing 20 mM
sodium citrate and 1 mM ethylenediaminetetraacetic acid (EDTA)
(pH 6.0). The ﬁnal reaction mixture contained test compound at
a range of concentrations: TbPTR1 (4.8 nM), H2B (0.35 lM), cyt c
(81 lM), and NADPH (100 lM). The ﬁnal assay volume was
200 ll in 96-well clear polystyrene plates with a ﬁnal dimethyl
sulfoxide (DMSO) level of 1% in all samples, including controls.
TbDHFR-TS activity was assayed in a buffer containing 20 mM
sodium citrate and 1 mM EDTA (pH 7.4). The ﬁnal reaction mixture
contained test compound at a range of concentrations: TbDHFR-TS
(1 nM), H2F (4.4 lM), cyt c (81 lM), and NADPH (100 lM). The ﬁ-
nal assay volume was 200 ll in 96-well clear polystyrene plates
with a ﬁnal DMSO level of 1% in all samples, including controls.
All reagents were solubilized in assay buffer with the exception
of H2B, which was solubilized in 0.2 M NaOH. The ﬁnal assay con-
centration of NaOH was 70 lM.
Novel screening assay protocol: Liquid handling
Test and standard compounds were cherry-picked into the ﬁrst
column of a 96-well polypropylene plate and then serially diluted
in 100% DMSO through 10 half-log increments in row orientation
using a JANUS eight-channel Varispan automated workstation
(PerkinElmer). This produced working stock (100 ﬁnal concentra-
tion in assay) compound plates with six test compound curves and
two standard compound curves occupying columns 1 to 10. Ali-
quots (2 ll) of each compound working stock were then stamped
into replicate clear 96-well polystyrene assay plates using a Plate-
Mate 2  2 pipetting workstation (Thermo Fisher).
Then20 ll of cyt c (stock concentrationof 810 lMinassaybuffer)
was added to all wells using the JANUS MDT I200 96-well head
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strate (stock concentrations of 5.5 nM and 0.4 lM for TbPTR1 and
1.12 nM and 5 lM for TbDHFR-TS, respectively) was then added to
columns 1 to 11 only using the same instrument. Buffer containing
substrate only was added to column 12 to provide the no-enzyme
control. In all liquid handling steps for reagent addition, tips were
washed between each transfer and changed after two transfers.
The reaction was started by the addition of 2 ll of NADPH (stock
concentration of 100 lM) using a FlexDrop reagent dispenser
(PerkinElmer). Each plate was started at 1-min intervals in accor-
dance with the time taken to read a plate. The TbPTR1 assay was
run for 50 min, the TbDHFR assay was run for 40 min, and the
absorbance was read at 550 nm using a Victor3 multilabel plate
reader (PerkinElmer).
Spectrophotometric assay for TbPTR1
Veriﬁcation of catalytic activity of TbPTR1 was carried out as de-
scribed by Dawson and coworkers [16]. Brieﬂy, solutions containing
TbPTR1(82.5 nM)andH2B (20 lMin0.2 MNaOH)werebufferedwith
20mM sodium citrate (pH 4.7). The reaction was executed in a 1-ml
cuvette (990 ll) and initiatedwith100 lMNADPH(10 ll). Adecrease
in absorbance was followed spectrophotometrically at 340 nm.
HPLC assay for TbPTR1
TbPTR1 activitywas assayed by directlymeasuring the formation
of H4B from H2B at 22 C using a previously described HPLC-based
method [18] with modiﬁcations. Assays were carried out in
20 mM sodium citrate (pH 6.0) (for direct comparison with the
screening assay) containing 1 mM EDTA and 50 lM NADPH cofac-
tor. Aliquots (100 ll) of enzymatic reactions were made alkaline
by the addition of 46 mM NaOH and oxidized in the presence of
12 mM KI/4.4 mM I2 in the dark at 22 C for 1 h. Under these condi-
tions, H2B and H4B were oxidized to biopterin and pterin, respec-
tively [18,19]. Excess iodine was removed by the addition of
12 mM ascorbate. Neopterin (25 nM) was added as internal stan-
dard. Sampleswere then acidiﬁedwith 83 mMHCl, and precipitated
proteins were removed by centrifugation (16,000g, 10 min, 22 C).
Supernatants were analyzed by reverse-phase HPLC on an ion-
paired Ultrasphere C18 column using a Dionex UltiMate 3000 sys-
tem coupled to a Dionex RF-2000 ﬂuorometer. The mobile phase
contained 20 mM sodium phosphate and 4 to 10% methanol with
a ﬂow rate of 1 ml min1. Pterins were detected ﬂuorometrically
using excitation and emission wavelengths of 360 and 440 nm,
respectively. Products were quantiﬁed against pterin standards
whose concentrations were determined using published extinction
coefﬁcients [20]. The linearity of the assay was established by mea-
suringH4B formation over time (15–180 s) in the presence of 1.1 nM
TbPTR1 using 10 and 500 nM H2B. The enzyme proportionality of
the assay was investigated by measuring H4B produced in 1 min
by varying concentrations of TbPTR1 (0.31–10 nM) using constant
substrate (25 nM H2B). The linearity of the data sets was analyzed
by linear regression. The Km for H2B was determined by measuring
H4B produced in 1 min by 1.1 nM TbPTR1 using varying concentra-
tions of H2B (3–300 nM). The IC50 for MTXwas determined bymea-
suring H4B produced in 1 min by 1.1 nM TbPTR1 at [S] = Km in the
presence of varying concentrations of MTX.
Crystallography
In preparation for crystallization, TbPTR1 was concentrated to
6 mg ml1 in 20 mM Tris–HCl (pH 8.0). The ligand DDD00066641
was solubilized to a concentration of 200 mM in DMSO. The ter-
nary complex of TbPTR1 with cofactor and ligand was prepared
by incubating the protein solution (6 mg ml1) with 2 mM of theligand, 1 mM NADP+, and 20 mM dithiothreitol in 20 mM Tris–
HCl (pH 8.0) at 4 C for 30 min prior to crystallization.
Crystallization was carried out by the vapor diffusion method
by mixing 2 ll of the protein solution with 2 ll of the reservoir
solution and incubating the drops over 100 ll of the reservoir in
sitting drop plates. The reservoir solution consisted of 1.5–3.0 M
Na acetate and 0.1 M citrate buffer (pH 4.5–6.0). Diffraction quality
crystals were obtained after incubation for 2 to 3 days at 18 C.
Diffraction data were collected using a rotating anode X-ray
source (RigakuMicromax 007) and an image plate detector (Rigaku
R-AXIS IV++). Crystals were prepared for data collection by transfer-
ring them through a cryoprotection solution of mother liquor plus
20% glycerol and then were ﬂash frozen in a stream of gaseous
nitrogen at 100 K. Data were integrated and scaled using MOSFLM
[21] and SCALA [22] from the CCP4 [23] suite of programs.
Molecular replacement, as implemented in MOLREP [24], was
used to solve the structure using the protein chains from the
TbPTR1/MTX complex [16] (Protein Data Bank [PDB] 2C7V) as the
starting model. After the molecular replacement step, a round of ri-
gid body reﬁnement was carried out using REFMAC5 [25]. Ligand
models and associated topology ﬁles were created with PRODRG
[26] and were built into Fo  Fc electron density maps using COOT
[27]. Further rounds of restrained reﬁnement were carried out
using REFMAC5 and manual alteration of the models, including
the addition of solvent molecules using COOT. Coordinates and
structure factors for TbPTR1 plus DDD000066641 have been depos-
ited in the PDB with accession code 2VZ0.
Data analysis
For determination of Km, data were ﬁtted by nonlinear regres-
sion in GraFit to the following general equation for substrate
inhibition:
m ¼ Vmax
1þ KmS þ SKSi
: ð1Þ
For determination of IC50 for inhibitors, all routine curve ﬁtting
was undertaken using a four-parameter logistic dose–response
curve (model 205) in XLFit 4.2.
For MTX potency determination, data were ﬁtted in GraFit to
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where vi and v0 are the rates with and without inhibitor, [E]T is
the total enzyme concentration (a ﬁxed parameter), [I]T is the total
inhibitor concentration, and Kiapp is the apparent inhibitor constant.
For competitive inhibitors,





For routine assessment of potency for tight-binding inhibitors
identiﬁed through test compounds, BatchKi software (BioKin) was
used todetermineKiapp. AmodiﬁedMorrisonequation [29]wasused
as the ﬁttingmodel inwhich vb is the background enzymatic rate, v0
is the ‘‘full” catalytic signal in the absence of inhibitor, [E]0 is the
active enzyme concentration, and [I]T is the inhibitor concentration:
m ¼ mb þ m0

½E0  ½IT  Kappi þ
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½E0  ½IT  Kappi




The BatchKi software automatically determined initial estimates
of Kiapp based on a weighted average algorithm [30]. First-round
analysis treated the active enzyme concentration as a ﬁxed
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tight-binding inhibitors, a second round of analysis allowed deter-
mination of the enzyme active site concentration, where [E]0 is
treated as an adjustable parameter [31]. The optimization of [E]0
was performed within preset limits (±5*[E]0). The data-ﬁtting algo-
rithm used in BatchKi software was either Reich’s modiﬁcation [32]
of the Levenberg–Marquardt method [33] or a robust regression
algorithm [34] based on Huber’s minimax method [35].
The Z0 factor for control data on each screening plate was calcu-
lated as deﬁned by Zhang and coworkers [36], where lHI and lLO
are the means and rHI and rLO are the standard deviations for
the positive and negative control wells, respectively:
Z0 ¼ 1 3ðrHI þrLOÞ
lHI  lLO
: ð5ÞResults
Reduction of cyt c Fe3+ as a read-out of PTR1 activity in vitro
Previously, Hasegawa and coworkers [37] demonstrated that
H4B could be oxidized by ferricytochrome c (cyt c Fe3+) via a trihy-
drobiopterin radical intermediate to form quinonoid H2B (qH2B)
and cyt c Fe2+ (Fig. 1). The formation of reduced cyt c Fe2+ can be
monitored as an increase in absorbance at 550 nm. Therefore, we
investigated whether this reaction could be adopted to enable
detection of the product of the PTR1 and DHFR-TS enzyme
reactions.
We ﬁrst determined ‘‘proof of concept” for the coupling assay
using a standard ultraviolet–visible (UV–Vis) spectrophotometer
(Fig. 2A). The absorbance proﬁle of cyt c Fe3+ and cyt c Fe2+ was
determined. Cyt c Fe2+ produced by an excess of solid sodium
dithionite was conﬁrmed to be a narrow deﬁned peak at 550 nm,
accompanied by the formation of an additional shallower and
broader peak at 520 nm. A similar spectrum was obtained on
reduction with H4B but not with H2B (not shown). However, H2B
was able to reduce cyt c Fe3+ in the presence of TbPTR1 and NADPH
in a time-dependent manner (Fig. 2A).Development of a microtiter plate-based screening assay
From this point forward, all work was carried out in a 96-well
plate format with a Victor3 multilabel plate reader (PerkinElmer)
using a 550 ± 9-nm ﬁlter. The optimum pH for the coupled assay
was determined to be pH 6.0 in either citrate or phosphate buffer
(Fig. 2B). Cyt c concentrations greater than 50 lM gave maximalFig. 1. Principle of the cyt c-coupled assay for TbPTR1. H2B is reduced by NADPH (e340nm
Fe3+ to cyt c Fe2+ (De550nm = 21.1 mM1 cm1) and qH2B [20]. Under anaerobic condition
aerobic conditions [19], leading to an increase in absorbance signal of 5- to 6-fold. qH2B irates of reduction (Fig. 2C), and rates of cyt c reduction are propor-
tional to enzyme activity up to 25 nM (Fig. 2D).
Following a lag period, reduction of cyt c was linear from 20 to
60 min (r2 = 0.9994) and, therefore, was suitable for kinetic analy-
ses (Fig. 3). The increase in A550nm over this period in the absence of
TbPTR1 was negligible and indicates that NADPH itself does not
signiﬁcantly reduce cyt c. For routine inhibitor screening, plates
were read after 50 min to ensure that a maximal signal was
achieved. At this time point, 23.9 lM of product (cyt c Fe2+) had
been formed from 0.35 lM H2B in the reaction mixture. Based on
the stoichiometry of 1.5 to 1.8 for reduction of cyt c by H4B under
aerobic conditions, H2B had been cycled 40–46 times after 50 min,
and measuring linear rates of reaction between 20 and 50 min, the
signal-to-background ratio for the assay was determined to be 43.
Given that not more than 10% of H2B can be used in the direct as-
say, when measuring the initial linear rate of absorbance change at
340 nm due to the oxidation of NADPH, it is evident that the cou-
pled assay is approximately 400-fold more sensitive than the direct
assay method.
Termination of the reaction can be achieved with 10 ll of NaOH
(0.2 mM), although use of a rapid read plate reader dispensed with
the need for this additional step in our studies. Initial performance
statistics of the microtiter plate-based assay demonstrated its clear
potential for routine compound assessment purposes, yielding
highly acceptable Z0 values (Table 1).Determination of kinetic parameters
Using the coupled assay, the linear rate of product formation
was measured over a wide range of H2B concentrations. The result-
ing plot of rate versus substrate concentration revealed pro-
nounced inhibition by H2B (Fig. 4), as reported previously for the
T. brucei [16] and L. major enzymes [11]. Fitting the data to the
standard equation for substrate inhibition (Eq. (1)) gave an appar-
ent Km (Kmapp) of 151 ± 50 nM, a substrate inhibition constant (Kis)
of 439 ± 135 nM, and a kcat of 0.0016 ± 0.0003 s1. These kinetic
parameters are considerably lower than those reported previously
[16] but were determined at pH 6.0 (optimal in this assay format)
rather than at the previously reported pH optimum of 3.7.
To conﬁrm the validity of the coupled assay, kinetic parameters
with respect to substrate were also determined using an alternative
HPLC-based assay for PTR1 activity determination (Fig. 5). Using this
method, formationofH4Bproductwas stoichiometricwith thedisap-
pearance of H2B, linear for at least 2 min across the assay range
(Fig. 5A), and ratesdeterminedafter 1 minof incubationwerepropor-
tional to enzyme up to at least 5 nM TbPTR1 (r2 = 0.9999) (Fig. 5B). As
notedpreviously, theenzymeis inhibitedathighsubstrateconcentra-= 6.22 mM1 cm1) and TbPTR1 to H4B, which then nonenzymatically reduces cyt c
s, the stoichiometry is 2 mol cytochrome c/mol NADPH and 1.5- to 1.8-fold under
s unstable at near neutral pH and spontaneously isomerizes principally to H2B [20].
Fig. 2. Optimization of the cyt c-coupled assay for TbPTR1. (A) Reduction of cyt c by TbPTR1 activity. The absorbance spectrum of cyt c (80 lM) was measured at intervals (20,
40, and 60 min) in the presence of TbPTR1 (20 nM), H2B (0.5 lM), and NADPH (100 lM) using a cuvette-based assay. Controls omitting one of the components give identical
spectra to the zero time trace (not shown). Na+ dithionite was added to completely reduce residual cyt c. (B) Determination of optimum pH. Assays contained 4.8 nM TbPTR1,
0.35 lM H2B, 80 lM cyt c, and 100 lM NADPH in a range of buffers—Na+ citrate (closed circles), Na+ phosphate (open squares), and Tris (closed squares) (all at 20 mM)—
containing 1 mM EDTA adjusted to different pH values with citric acid, phosphoric acid, and Na+ hydroxide, respectively. Absorbance at 550 nm was measured after 60 min.
(C) Determination of optimum cyt c concentration. Assays contained 4.8 nM TbPTR1, 0.35 lMH2B, and 100 lMNADPH in 20 mM Na+ citrate/1 mM EDTA buffer (pH 6.0) with
varying cyt c concentrations. Absorbance at 550 nm was measured after 60 min. (D) Proportionality of activity with enzyme concentration. Assays contained varying
concentrations of TbPTR1, 0.35 lMH2B, 80 lM cyt c, and 100 lMNADPH in 20 mMNa+ citrate/1 mM EDTA buffer (pH 6.0). Absorbance at 550 nmwas measured after 60 min.
mAbs, monoclonal antibodies. Each data point shown is the mean ± standard deviation of triplicate determinations.
Fig. 3. Time-based linearity of cyt c-coupled assay for TbPTR1. Using ﬁnal assay
conditions described in Materials and Methods, signal generation was measured
across a time course. Open symbols: plus enzyme (4.8 nM); closed symbols: minus
enzyme. The dotted line is the linear regression of the change in absorbance at
550 nm from 20 to 50 min. Data shown are from a representative experiment that
was reproduced on three independent occasions. Each data point shown is the
mean ± standard deviation of 16 replicates.
Table 1
Statistical analysis of plate data.
TbPTR1 TbDHFR-TS
High signal (absorbance units) 0.44 ± 0.02 0.43 ± 0.02
Low signal (absorbance units) 0.32 ± 0.01 0.33 ± 0.01
Signal/Background ratio (>1.2)a 1.39 ± 0.04 1.30 ± 0.03
Z0 (>0.5)b 0.77 ± 0.08 0.67 ± 0.08
Note. Shown are assay performance statistics of TbPTR1 and TbDHFR-TS in the cyt
c-coupled assay. The assay was carried out in 96-well plates using sodium citrate/
EDTA buffer at pH 6.0 and pH 7.4 for TbPTR1 and TbDHFR-TS, respectively. Data
shown are means ± standard deviations from 26 plates of assay development and
mock screening plates. Values in parentheses represent thresholds of acceptance for
screening plate approval.
a When the signal/background ratio is calculated using reaction rates in the
presence and absence of enzyme, a typical ratio for the assay is 43.
b Eq. (5) [36].
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10.4 nM, and kcat = 0.070 ± 0.013 s1 (Fig. 5C and D). The 7-fold dis-
crepancy in Kmapp between the coupled recycling assay and the HPLC
assay most likely reﬂects the fact that, under steady-state conditions
in the coupled assay, the biopterin substrate is present as amixture of
H2B, H4B, and qH2B (see Fig. 1).
For standard inhibitor screening, it is ideal to run an assay at or
below Km for competing substrate to maximize the chances ofidentifying activity. However with signiﬁcant substrate inhibition
and limited signal-to-background ratio in this assay, an H2B con-
centration giving an optimal window of signal in the coupled assay
was selected for routine screening. The second substrate, NADPH,
was saturating in both assays given that the Kmapp is 1.6 ± 0.1 lM,
as determined by the HPLC assay method (data not shown).
Based on these studies, the ﬁnal optimized assay conditions
used for compound screening were deﬁned as 0.3 lM H2B,
100 lMNADPH, 81 lM cyt c Fe3+, and 4.8 nM TbPTR1 in 20 mM so-
dium citrate buffer plus 1 mM EDTA (pH 6.0). These conditions
were expected to be conducive to the identiﬁcation of inhibitors
binding at the substrate site of TbPTR1.
Fig. 4. Determination of Kmapp for H2B using the coupled assay. (A) Enzyme rate versus substrate concentration. The curve represents the best nonlinear ﬁt to the general
equation for substrate inhibition. (B) Lineweaver–Burk transformation of data. The resulting kinetic parameters were as follows: Km = 167 ± 54 nM, Kis = 439 ± 135 nM,
Vmax = 0.51 ± 0.10 pmol min1, and kcat/Km = 5.6  105 M1 s1. Data shown are from a representative experiment that was reproduced on three independent occasions. Each
data point shown is the mean of duplicate determinations.
Fig. 5. TbPTR1 assay by HPLC. All assays were carried out in 20 mM citrate, 1 mM EDTA, and 50 lM NADPH (pH 6.0) with speciﬁed concentrations of H2B and initiated with
TbPTR1. Formation of H4B product was determined by HPLC as described in Materials and Methods. (A) Linearity of assay at high and low substrate concentrations. Assays
contained 1.1 nM TbPTR1, and reactions were terminated at the speciﬁed time intervals. Open circles: 10 nM; closed circles: 500 nM H2B. (B) Proportionality of activity with
enzyme concentration. Assays contained 25 nM H2B, and reactions were terminated after 1 min. (C) Enzyme rate versus substrate concentration. Assays contained 1.1 nM
TbPTR1, and reactions were terminated after 1 min. The curve represents the best nonlinear ﬁt to the high substrate inhibition equation. (D) Lineweaver–Burk transformation
of kinetic data. The resulting kinetic parameters were as follows: Km = 25.0 ± 6.7 nM, Kis = 37.2 ± 10.4 nM, Vmax = 4.7 ± 0.9 pmol min1, and kcat/Km = 2.8  106 M1 s1. Data
points represent the means and standard deviations of triplicate measurements. Data shown are from representative experiments that were reproduced on three independent
occasions. Each data point shown is the mean of triplicate determinations.
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Further validation of the coupled assay was obtained through
the use of the established antifolate MTX as a standard inhibitor.
An average IC50 of 13.7 ± 2.1 nM (n = 16) and a Hill slope of
1.19 ± 0.14 (n = 16) were determined using the newly developed
screening assay (Fig. 6A). Given the enzyme concentration
(4.8 nM), MTX potency is within tight-binding territory [38].
Therefore, Kiapp analysis was undertaken to report potencies moreaccurately (Eq. (2)). The corresponding Kiapp was 11.1 ± 2.1 nM.
MTX potency against TbPTR1 was validated using the HPLC assay,
yielding an IC50 of 8.2 ± 0.2 nM and a Kiapp of 7.1 ± 1.0 nM. Based
on the Kmapp and H2B concentrations used in the respective assays
(Eq. (3)), the Ki values for MTX were in excellent agreement (4.1
and 3.6 nM for the coupled and HPLC assays, respectively).
Furthermore, Fig. 6B shows a typical concentration–effect curve
in the screening assay for a compound representing one of the novel
chemical series identiﬁed through our medicinal chemistry efforts.
Fig. 6. Inhibition of TbPTR1 by MTX and DDD00066641. (A) Concentration-dependent inhibition by MTX. MTX potency was determined using the cyt c-coupled assay (open
circles, n = 16) and the HPLC assay (closed circles, n = 3). For the coupled assay, the mean IC50 was 13.7 ± 2.1 nM and the Hill slope was 1.19 ± 0.14. The corresponding Kiapp
was 11.1 ± 2.1 nM. For the HPLC assay, the corresponding values were IC50 = 8.22 ± 0.21 nM, Hill slope = 2.1 ± 0.1, and Kiapp = 7.1 ± 1.0 nM. (B) Concentration-dependent
inhibition by DDD00066641 as determined using the cyt c method. The IC50 value was 10.6 nM, the Hill slope was 0.98, and the corresponding Kiapp was 9.8 ± 2.6 nM.
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To produce an effective therapy for HAT, it is possible that inhi-
bition of both TbPTR1 and TbDHFR-TS will be required. Therefore,
the application of the coupled assay to measure DHFR activity
in vitro was investigated. The coupled assay format was found to
support the measurement of both human and TbDHFR-TS activity,
in particular using a sodium citrate buffer (pH 7.4) to optimize the
window of signal achievable.
Under these conditions, activity was proportional up to at least
15 nM TbDHFR-TS (Fig. 7A) and the assay was linear between
approximately 2 and 55 min. The enzyme displayed normal
Michaelis–Menten kinetics, with H2F as substrate yielding a Kmapp
of 7.3 ± 1.5 lM (Fig. 7B and C). MTX was shown to be a very potent
inhibitor of TbDHFR-TS, with an average IC50 of 0.64 nM ± 0.28 nM
and an average Hill slope of 0.78 ± 0.08 (n = 16) (Fig. 7D). Because
MTX proved to be a tight-binding inhibitor of TbDHFR-TS, the cor-
responding Kiapp was calculated for MTX to be 0.24 ± 0.14 nM,
yielding a Ki of 0.15 nM.
The assay performance statistics generated from assay develop-
ment and mock screening studies for the DHFR assay are shown in
Table 1. As for the PTR1 assay, they yielded readily acceptable Z0
values.
Lead generation for TbDHFR-TS and TbPTR1
The program was initiated using two approaches: ligand-based
design and in silico screening. The identiﬁcation and optimization
of PTR1 and DHFR-TS inhibitory activity were underpinned by data
provided by the newly developed screening assay and structure-
guided chemistry design. Throughout the project, potency values
(Kiapp from 10-point concentration–effect curves, n = 2) were gen-
erated for TbPTR1, TbDHFR-TS, and (for selectivity purposes) hu-
man DHFR (Eq. (4)). Fig. 8 illustrates the high level of correlation
observed between replicate potency values for a sample of test
compounds in both PTR1 and DHFR-TS assays. These data provided
early conﬁdence that the assay developed could robustly support
the development of structure–activity relationships for the com-
pound series investigated. Fig. 8C illustrates the highly consistent
performance of the PTR1 assay with respect to the key metrics of
Z0 and MTX potency over a time period spanning 18 months. The
ultimate validation of this novel screening assay was conﬁrmed
on demonstration that compounds identiﬁed as actives using the
new assay were in fact legitimately binding to TbPTR1.
This is exempliﬁed using compound DDD00066641 (6-p-tolyl-
quinazoline-2,4-diamine), which was identiﬁed as a potent inhibi-
tor of TbPTR1 using the coupled assay, with an average Kiapp of9.8 ± 2.6 nM (Fig. 6B). For a competitive inhibitor, Ki = Kiapp (1 + S/
Km), yielding a Ki of 3.0 ± 0.8 nM. The structure of the ternary com-
plex of TbPTR1 with this ligand and the cofactor NADP+ was ob-
tained by cocrystallization (Fig. 9A). The binding mode of the
ligand is similar to that observed for MTX bound to TbPTR1 [16],
with the diaminoquinazoline ring of DDD00066641 sandwiched
between the nicotinamide ring of the cofactor and the side chain
of Phe97 (Fig. 9B). The diaminoquinazoline ring of DDD00066641
also shows an identical pattern of H-bond interactions to the pro-
tein chain and cofactor, as observed for the pteridine ring of MTX.
The ligand forms three H-bonds to the protein: the 2 amino group
interacting with both the main chain carbonyl and side chain hy-
droxyl of Ser95 and the 4 amino group interacting with the side
chain hydroxyl of Tyr174. Two H-bonds are also formed via the
N1 atom to the a-phosphate group and from the N3 atom to the
nicotinamide ribose 20 hydroxyl. The hydrophobic toluene substi-
tuent packs against a hydrophobic surface formed by the side
chains of Leu209, Pro210, Met213, and Tyr221.
The medicinal chemistry program to date has yielded a number
of compound series with single digit nanomolar Kiapp values for
TbPTR1. Furthermore, individual series have been developed with
equipotent, TbPTR1-selective, and TbDHFR-TS-selective proﬁles
providing the potential to comprehensively probe the biology of
pterin and folate metabolism in the African trypanosome.
Routine cocrystallization studies with TbPTR1 across these series
have repeatedly conﬁrmed the binding mode revealed for
DDD00066641.Discussion
In this article, we have presented the development and valida-
tion of a nonenzymatically coupled microtiter plate-based assay
for PTR1 and DHFR-TS. The assay was developed to enable a drug
discovery project to identify and develop small-molecule inhibitor
series of both PTR1 and DHFR-TS in the African trypanosome. The
assay platform described in this article was thoroughly validated as
an accurate read-out of PTR1 and DHFR-TS activity in vitro through
a number of experimental approaches.
The potency of a known inhibitor, MTX, observed against
TbPTR1 using the novel screening assay (IC50 = 13.7 ± 2.1 nM) was
in good agreement with the potencies reported for L. major
[10,11,39], Leishmania tarentolae [39], and Trypanosoma cruzi
[40]. Similarly, the IC50 of MTX observed against TbDHFR-TS using
the coupled assay (IC50 = 0.64 ± 0.28 nM and Ki = 0.15 nM) was in
agreement with the IC50 values reported for human, Escherichia
coli, and Pneumocystis carinii DHFR-TS enzymes [41]. Further
Fig. 7. Summary of TbDHFR-TS assay development for the cyt c-coupled assay method. (A) Proportionality of TbDHFR-TS activity with enzyme concentration. (B) Enzyme rate
versus substrate concentration. (C) Lineweaver–Burk transformation of data. (D) IC50 for MTX. The average MTX IC50 (n = 16) against TbDHFR-TS was 0.64 nM ± 0.28 nM, and
the Hill slope was 0.78 ± 0.08. The corresponding Kiapp was 0.24 ± 0.14 nM. mAbs, monoclonal antibodies. Data shown are from representative experiments that were
reproduced on three independent occasions. Each data point shown is the mean of duplicate determinations from two independent experiments.
Fig. 8. Longitudinal performance monitoring of the novel screening assay. Concentration-dependent inhibition was determined for all compounds screened against TbPTR1
and TbDHFR-TS. Brieﬂy, serial dilution curves (10-point curves, 1:3 dilutions in DMSO) were created and assayed in duplicate using the cyt c-coupled assay. All assays were
performed as described in Materials and Methods. The correlation between replicate pKiapp (log Kiapp) values is shown for TbPTR1 (A) (n = 137 compounds) and TbDHFR-TS
(B) (n = 80 compounds). (C) Performance of the cyt c-coupled assay across a period of 18 months. Closed circles: Z0 values; open circles: MTX pKiapp values from all assay
plates.
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Fig. 9. Cocrystallization of key compounds with TbPTR1: Detailed views of the TbPTR1 active site in complex with NADPH and DDD00066641. (A) Binding mode of
DDD00066641 (green carbon atoms) and the cofactor NADPH (cyan carbon atoms) in the active site (gray carbon atoms). Omit electron density, calculated after one round of
reﬁnement with the ligand atoms removed from the model, is shown as green mesh, contoured at 3 sigma. Key residues are labeled for clarity. (B) Binding mode of
DDD00066641 (green carbon atoms) superimposed on the binding mode of MTX (pink C atoms). Hydrogen bonds between the ligand and the protein/cofactor are shown as
dashed lines, and key residues are labeled for clarity. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to theWeb version of this article.)
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orthogonal platform for TbPTR1. The HPLC assay for PTR1 yielded
an IC50 of 8.2 ± 0.2 nM, again in excellent agreement with that pro-
duced by our screening assay. Calculation of Ki values taking into
account tight-binding behavior and substrate load of the respective
assays produced nearly identical values (4.0 and 3.5 nM for screen-
ing and HPLC assays, respectively).
Analysis and comparison of PTR1 and DHFR-TS substrate Km
values between assay platforms revealed some interesting obser-
vations. Whereas DHFR-TS enzymes are restricted in their sub-
strate repertoire, primarily reducing H2F to H4F, PTR1 can reduce
numerous pterins and folates. Furthermore, there are substantial
interspecies differences in PTR1 activity and substrate sensitivities
[42]. Substrate inhibition of TbPTR1 in response to H2B has also
been reported in both TbPTR1 and LmPTR1 [16] but has not been
reported for DHFR-TS in any species. Consistent with the literature,
substrate titrations at a ﬁxed enzyme concentration identiﬁed sub-
strate inhibition of TbPTR1 (with H2B) but not of TbDHFR-TS. The
Km
app for TbDHFR-TS determined in the screening assay agrees well
with literature reports [43–45].
The Kmapp for TbPTR1 in the screening assay was determined to
be 167 ± 54 nM, which is considerably lower than the previously
reported Km for TbPTR1 (10.9 ± 2.4 lM) [16]. However, the Kmapp
was determined at pH 6.0 in the current study, not at pH 3.7 as de-
scribed by Dawson and coworkers [16]. To support the determina-
tion of Km using the screening assay, Km was also determined using
the HPLC assay at pH 6.0. Substrate inhibition with respect to H2B
was also observed in the HPLC assay, and a nanomolar Kmapp was
determined (25 ± 6.7 nM). This small shift in apparent afﬁnity for
substrate between the screening assay and the HPLC assay is most
likely a result of the mixture of biopterin species present in the
coupled assay (H2B and qH2B) that are not present at steady-state
levels in the HPLC assay. It is also possible that the mixture of spe-
cies in the coupled assay contributes signiﬁcantly to the initial lag
phase observed, with qH2B possibly being a more efﬁcient sub-
strate for PTR1 than H2B itself and linearity being achieved only
after a steady state of these species has been attained. In support
of this notion, the lag phase is considerably shorter in the equiva-
lent DHFR assay.
The ultimate validation of the ability of a screening assay to
robustly identify inhibitors is in the conﬁrmation of identiﬁedactives as genuine binders to the target in question.We have shown,
using cocrystallization studies, that an example small molecule
identiﬁed using the screening assay described here binds to TbPTR1
through interactions within the pterin binding pocket in a manner
similar to that observed for MTX. Furthermore, the structure–activ-
ity relationships developed and informed by data generated by the
screening assay conform well to the binding modes identiﬁed for
multiple series through similar cocrystallization studies.
Another key attribute for a screening assay is that it should be
deemed as ﬁt for purpose. This screening assay was developed to
enable a structure-guided medicinal chemistry project and, there-
fore, was required to produce accurate reproducible (n = 2) potency
data for up to three targets (TbPTR1, TbDHFR-TS, and human DHFR)
for up to 20 compounds each week for a period of at least
12 months. We have demonstrated in this article that the platform
developed was able to consistently produce assay statistics that
were highly acceptable in terms of individual plate Z0 values and
returned potency values for the known inhibitor MTX that were
within expectations based on comparison with literature and alter-
native assay platforms. Furthermore, these key performance met-
rics were maintained longitudinally over the time period of the
project, allowing high levels of plate approval and minimal resc-
reening. Across a period of 18 months, the project produced
approximately 1500 approved concentration–effect curves
employing the novel screening assay.
In summary, we have developed a screening assay that is suit-
able for routine inhibitor assessment for both PTR1 and DHFR-TS
targets. The assay principle relies on H4B and H4F, the products of
catalysis by TbPTR1 and TbDHFR-TS, respectively, reducing cyt c
and resulting in an increase in signal at 550 nm. Unlike the conven-
tional spectrophotometric absorbance assay measuring oxidation
of NADPH at 340 nm, the novel assay provides the throughput, en-
hanced sensitivity, and extended period of linearity required of an
end-point drug discovery screening assay. We believe that the en-
hanced sensitivity and extended window of linearity are the result
of a cycling reaction involving H4B, which itself reduces cyt c form-
ing qH2B and which can subsequently dissociate to H2B. The HPLC
assay also described in this article will be used to support detailed
mode of inhibition studies for key compounds. Full details of enzy-
matic and biological activities of inhibitors discovered using this as-
say method will be published separately [46].
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